Pharma & Biotech

Valneva's recently published 2025 annual results reveal a company at a strategic crossroads. While its core business demonstrates resilience, the...

Investors in Bluechiip Limited have now received definitive confirmation of a total loss. The company's journey, which began with the...

The year 2026 is shaping up to be a decisive period for BioNTech as it seeks to solidify its transition...

ImmunityBio is advancing the commercial potential of its flagship therapy, ANKTIVA, with a new regulatory submission to the U.S. Food...

While Siemens Healthineers has achieved a significant diagnostic breakthrough with its new blood-based Alzheimer's tests, investor focus remains firmly fixed...

The German biotechnology firm Evotec SE finds itself at a critical juncture, marked by a significant clinical milestone that starkly...

The Canadian cannabis sector witnessed a significant consolidation on March 16, 2026, as Canopy Growth Corporation finalized its takeover of...

The biotechnology firm BioNxt Solutions continues to announce the kind of progress that typically attracts investor interest: new patents and...

Investors in Formycon are currently facing a contradictory set of developments. The stock price plunged to a new 52-week low...

In the specialized markets for cannabis and psychedelics, Hytn Innovations is pursuing a distinct strategy: adhering to stringent pharmaceutical-grade standards....